Pembrolizumab or placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: An updated analysis of KEYNOTE-859 for patients enrolled in Asia.

被引：0
|
作者：
Yen, Chia Jui
Oh, Do-Youn
Bai, Yuxian
Ryu, Min-Hee
Lee, Jeeyun
Li, Jin
Yang, Lin
Yasui, Hisateru
Yabusaki, Hiroshi
Lam, Ka On
Yamaguchi, Kensei
Yeh, Kun-Huei
Yin, Lina
Leconte, Pierre
Bhagia, Pooja
机构：
[1] Natl Cheng Kung Univ Hosp, Tainan, Taiwan
[2] Seoul Natl Univ, Coll Med, Seoul, South Korea
[3] Harbin Med Univ Canc Hosp, Harbin, Peoples R China
[4] Univ Ulsan, Coll Med, Coll Med, Seoul, South Korea
[5] Samsung Med Ctr, Seoul, South Korea
[6] Tongji Univ, Sch Med, Shanghai East Hosp, Shanghai, Peoples R China
[7] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China
[8] Kobe City Med Ctr Gen Hosp, Kobe, Japan
[9] Niigata Canc Ctr Hosp, Niigata, Japan
[10] Queen Mary Hosp, Hong Kong, Peoples R China
[11] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[12] Natl Taiwan Univ, Natl Taiwan Univ Hosp & Grad Inst Oncol, Coll Med, Taipei, Taiwan
[13] Merck & Co Inc, Rahway, NJ USA
[14] MSD France, Courbevoie 92, France
[15] Yonsei Univ, Coll Med, Dept Internal Med, Div Med Oncol,Coll Med, Seoul 120752, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.464
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：464 / 464
页数：1
相关论文
共 50 条
  • [11] KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1-selected populations
    Rha, Sun Young
    Wyrwicz, Lucjan
    Weber, Patricio Eduardo Yanez
    Bai, Yuxian
    Ryu, Min-Hee
    Lee, Jeeyun
    Rivera, Fernando
    Alves, Gustavo Vasconcelos
    Garrido, Marcelo
    Shiu, Kai-Keen
    Fernandez, Manuel Gonzalez
    Li, Jin
    Lowery, Maeve Aine
    Cil, Timucin
    Cruz, Felipe Melo
    Qin, Shukui
    Yin, Lina
    Bordia, Sonal
    Bhagia, Pooja
    Oh, Do-Youn
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [12] Health-related quality of life (hrqol) analysis from KEYNOTE-859: First-line (1L) pembrolizumab (pembro) plus chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
    Lowery, M.
    Wyrwicz, L.
    Oh, D-Y.
    Shiu, K. K.
    Weber, P. Yanez
    Bai, Y.
    Lee, J.
    Rivera, F.
    Alves, G.
    Garrido, M.
    Fernandez, M. Gonzalez
    Li, J.
    Cil, T.
    Cruz, F.
    Qin, S.
    Yin, L.
    Valderrama, A.
    Bordia, S.
    Rha, S. Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S854 - S855
  • [13] Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
    Rha, Sun Young
    Oh, Do-Youn
    Yanez, Patricio
    Bai, Yuxian
    Ryu, Min-Hee
    Lee, Jeeyun
    Rivera, Fernando
    Alves, Gustavo Vasconcelos
    Garrido, Marcelo
    Shiu, Kai-Keen
    Fernandez, Manuel Gonzalez
    Li, Jin
    Lowery, Maeve A.
    Cil, Timucin
    Cruz, Felipe Melo
    Qin, Shukui
    Luo, Suxia
    Pan, Hongming
    Wainberg, Zev A.
    Yin, Lina
    Bordia, Sonal
    Bhagia, Pooja
    Wyrwicz, Lucjan S.
    LANCET ONCOLOGY, 2023, 24 (11): : 1181 - 1195
  • [14] KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma (vol 17, pg 2847, 2021)
    Tabernero, J.
    FUTURE ONCOLOGY, 2023, 19 (17) : 1229 - 1229
  • [15] First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study
    Qin, Shukui
    Bai, Yuxian
    Li, Jin
    Pan, Hongming
    Luo, Suxia
    Qu, Yanli
    Ye, Feng
    Yang, Lin
    Liu, Tianshu
    Li, Wei
    Chen, Xi
    Yang, Jianwei
    Ying, Jieer
    Lin, Xiaoyan
    Zhao, Lin
    Liang, Xinjun
    Mao, Yixiang
    Guo, Run
    Zuo, Yi
    Bordia, Sonal
    Li, Shouguo
    ADVANCES IN THERAPY, 2025, : 1892 - 1906
  • [16] KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma
    Tabernero, J.
    Bang, Y.
    Van Cutsem, E.
    Fuchs, C.
    Janjigian, Y.
    Bhagia, P.
    Li, K.
    Adelberg, D.
    Qin, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S101 - S102
  • [17] Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system
    Lang, Wenwang
    Deng, Lian
    Lu, Meijun
    Ouyang, Ming
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (08) : 1027 - 1042
  • [18] Q-TWiST analysis of pembrolizumab plus trastuzumab and chemotherapy for patients with metastatic HER2-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma in the KEYNOTE-811 trial.
    Rha, Sun Young
    Revil, Cedric
    Valderrama, Adriana
    Wang, Liya
    Andre, Manon
    McCarthy, Grant
    Young, Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 354 - 354
  • [19] Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
    Tabernero, Josep
    Van Cutsem, Eric
    Bang, Yung-Jue
    Fuchs, Charles S.
    Wyrwicz, Lucjan
    Lee, Keun Wook
    Kudaba, Iveta
    Garrido, Marcelo
    Chung, Hyun Cheol
    Salguero, Hugo Raul Castro
    Mansoor, Wasat
    Braghiroli, Maria Ignez Freitas Melro
    Goekkurt, Eray
    Chao, Joseph
    Wainberg, Zev A.
    Kher, Uma
    Shah, Sukrut
    Kang, SoonMo Peter
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18)
  • [20] First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): Analysis of KEYNOTE-590 and KEYNOTE-859 by tumor type.
    Shiu, Kai-Keen
    Rivera, Fernando
    Medley, Louise C.
    Aghmesheh, Morteza
    Dunne, Richard Francis
    Roy, Rajarshi
    Wyrwicz, Lucjan S.
    Larson, Timothy
    Metges, Jean-Philippe
    Mansoor, Wasat
    Goekkurt, Eray
    Moreira Antunes, Luiz Carlos
    Castro Oliden, Victor
    Jensen, Erin
    Shah, Sukrut
    Bordia, Sonal
    Bhagia, Pooja
    Lowery, Maeve Aine
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 345 - 345
12345